https://orcid.org/0000-0002-8427-9736
Figures & data
Figure 1. DB-induced cell apoptosis was reversed by ASP co-treatment. (a) MTT assay was used to examine cell proliferation, and (b, c) Western Blot analysis was performed to determine Cyclin D1 and CDK2 expressions. (d, e) Cell apoptosis ratio was measured by performing FCM assay through staining cells with Annexin V-FITC and PI. Each experiment had 3 repetitions, and * P < 0.05
Figure 2. The autophagy flux was activated by ASP in DB-treated hepatocytes. (a-c) The autophagy associated biomarkers were examined by Western Blot analysis. (d) MTT assay was used for cell proliferation evaluation. (e, f) Cell apoptosis was examined by FCM assay. Each experiment had 3 repetitions, and * P < 0.05
Figure 3. ASP activated the MEK/ERK pathway to trigger cell autophagy. We performed western blot analysis to examine the expression status of (a-d) Raf, Ras, p-MEK1, MEK1, p-ERK1 and ERK1, and (e-g) LC3BII/I ratio, Atg5 and p62 in the hepatocytes. Each experiment had 3 repetitions, and * P < 0.05
Figure 4. ASP regulated the MEK/ERK pathway to exerted its protective effects in DB treated hepatocytes. (a) SCH772984 suppressed cell proliferation in ASP and DB co-treated hepatocytes, as determined by MTT assay. (b, c) The expression levels of cyclin D1 and CDK2 were determined by western blot analysis. (d, e) FCM assay was used to evaluate cell apoptosis ratio in hepatocytes. each experiment had 3 repetitions, and * P < 0.05
